隋建華博士
隋建華實(shí)驗(yàn)室將基礎(chǔ)生物學(xué)研究與醫(yī)學(xué)應(yīng)用相結(jié)合，開展以人抗體為主的相關(guān)研究。
- 基本信息
- 教育經(jīng)歷
- 工作經(jīng)歷
- 研究概述
- 發(fā)表文章
隋建華 博士北京生命科學(xué)研究所研究員，生物制品中心和抗體中心主任Jianhua Sui, Ph.D. Assistant Investigator & Director of Biologics CenterNIBS, BeijingPhone：86-10-80726688-8630Fax： 86-10-80726021 E-mail：suijianhua@nibs.ac.cn
教育經(jīng)歷：
Education
|
2000 |
中國協(xié)和醫(yī)科大學(xué)中國醫(yī)學(xué)科學(xué)院 血液學(xué)研究所 病理生理學(xué)博士 |
|
|
|
Ph.D. Pathophysiology, Institute of Hematology, Peking Union Medical College & Chinese Academy of Medical Sciences, China
|
|
|
1997 |
蘭州大學(xué)醫(yī)學(xué)院心血管內(nèi)科學(xué)碩士 |
|
|
|
M.S. Cardiovascology, Lanzhou Medical School, Lanzhou University, China |
|
|
1994 |
蘭州大學(xué)醫(yī)學(xué)院 臨床醫(yī)學(xué)學(xué)士 |
|
|
|
B.S. Clinical Medicine, Lanzhou Medical School, Lanzhou University, China |
|
工作經(jīng)歷
Professional Experience
|
2012– |
北京生命科學(xué)研究所研究員，生物制品中心主任 |
|
|
Assistant Investigator and Director of Biologics Research Center National Institute of Biological Sciences, Beijing, China |
||
|
2004–2011 |
哈佛大學(xué) 醫(yī)學(xué)院 Dana-Farber癌癥研究所 講師 |
|
|
Instructor Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, US |
||
|
2000–2004 |
哈佛大學(xué) 醫(yī)學(xué)院 Dana-Farber癌癥研究所 博士后 |
|
|
Postdoctoral Fellow Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, US |
||
研究概述
Research Description
我們實(shí)驗(yàn)室/生物制品中心以重要感染性疾病，惡性腫瘤及自身免疫疾病為研究對(duì)象，將基礎(chǔ)生物學(xué)研究與醫(yī)學(xué)應(yīng)用相結(jié)合，開展以治療性抗體為主的相關(guān)研究。主要包括：1）發(fā)現(xiàn)和確認(rèn)新型治療性靶分子; 2）開發(fā)治療性人源抗體; 3）發(fā)展新型抗體工程技術(shù); 4）以抗體為主的生物大分子制備和抗體新藥臨床前研究及評(píng)估等。
Our laboratory and the Biologics Research Center conduct human antibody related researches at the intersection of biology and medicine. We take interdisciplinary approaches to develop innovative biologics for diseases prevention and therapy, mainly focus on infectious diseases, cancer andautoimmune diseases. Research programs include: 1) identification and validation of novel therapeutic targets; 2) development of therapeutic human monoclonal antibodies; 3) develop new antibody engineering technologies; 4) biologics production and pre-clinical validation of new antibody drugs, etc.
部分發(fā)表文章
Selected Publications (*Corresponding or co-corresponding author)
1. Li Y, Liu J, Chen W, Wang W, Yang F, Liu X, Sheng Y, Du K, He M, Lü X, Li H, Zhao L, Wei Z, Wang F, Zheng S, Sui J*. A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic efficacy and safety. J Hematol Oncol 2023, 16 (1) : 2.
2. Tian X, Liu X, Ding J, Wang F, Wang K, Liu J, Wei Z, Hao X, Li Y, Wei X, Zhang H, Sui J*. An anti-CD98 antibody displaying pH-dependent Fc-mediated tumour-specific activity against multiple cancers in CD98-humanized mice. Nat Biomed Eng 2023, 7 (1) : 8-23.
3. Liu X, Tian X, Hao X, Zhang H, Wang K, Wei Z, Wei X, Li Y, Sui J*. A cross-reactive pH-dependent EGFR antibody with improved tumor selectivity and penetration obtained by structure-guided engineering. Mol Ther Oncolytics 2022, 27 : 256-269.
4. Du K, Li Y, Liu J, Chen W, Wei Z, Luo Y, Liu H, Qi Y, Wang F, Sui J*. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther 2021, 29 (4) : 1572-1584
5. Yang F, Zhao L, Wei Z, Yang Y, Liu J, Li Y, Tian X, Liu X, , and Sui J*. A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects. J Immunol 2020, 205(8): 2156-2168
6. Li SB, Liu YY, Yuan L, Ji MF, Zhang A, Li HY, Tang LQ, Fang SG, Zhang H, Xing S, Li MZ, Zhong Q, Lin SJ, Liu WL, Huang P, Zeng YX, Zheng YM, Ling ZQ, Sui JH, Zeng MS. 2020. Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling. EMBO Mol Med: e12050
7. Liu H, Zheng S, Hou X, Liu X, Du K, Lv X, Li Y, Yang F, Li W, Sui J*. Novel antibodies targeting the N-terminus of FGF19 inhibit hepatocellular carcinoma growth without bile-acid-related side effects. Can Sci 2020,111(5):1750-1760
8. Qiao L, Sui J, Luo G. Robust Human and Murine Hepatocyte Culture Models of Hepatitis B Virus Infection and Replication. J Virol 2018, 92 (23).
9. Li D, He W, Liu X, Zheng S, Qi Y, Li H, Mao F, Liu J, Sun Y, Pan L, Du K, Ye K, Li W, Sui J*. A potent human neutralizing antibody Fc-dependently reduces established HBV infections. eLife 2017, 6: e26738.
10. Kang J, Wang J, Cheng J, Cao Z, Chen R, Li H, Liu S, Chen X, Sui J*, Lu F. Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance. Oncotarget 2017;8(34):56041-56050.
11. He W, Cao Z, Mao F, Ren J, Li Y, Li D, Li H, Peng B, Yan H, Qi Y, Sun Y, Wang F, Sui J*, Li W. Three amino acids modification in sodium taurocholate cotransporting polypeptide renders mice susceptible for infection of hepatitis D virus In vivo. J Virol 2016, 90 (19), 8866-74.
12. Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu QK, Marasco WA, Baric RS, Sims AC, Pyrc K, Li W, Sui J*. HCoV-HKU1 Spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs HE protein as a receptor-destroying enzyme. J Virol 2015, 89 (14), 7202-7213.
13. Sui J, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol 2014, 88 (23), 13769-80.
14. DK Chang, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge R, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell J, Zhu Q, Kupper T, Marasco WA. Humanization of an anti-CCR4 antibody that kills cutaneous T cell lymphoma cells and abrogates suppression by T regulatory cells. Molecular Cancer Therapeutics 2012,11 (11):2451-61.
15. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 1:e00049.
16. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide prevalence of heterosubtypic broadly neutralizing human anti-Influenza A antibodies. Clin Infect Dis 2011, 52 (8):1003-1009
17. Sui J*, Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Murakami A, Yammanuru A, Han T, Cox N, Bankston LA, Donis RO, Liddington RC and Marasco WA. Structural and functional basis for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16(3):265-73.
Comments in Nat Biotech, Nat Struct Mol Bio and Nat Med 2009.
18. Sui J*, Aird DR, Tamin A, Murakami A, Yan M, Yammanur, A, Jing H, Kan B, Liu, X, Zhu Q, Yuan Q, Adams GP, Bellini WJ, Xu J, Anderson LJ and Marasco WA. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-Coronavirus evolution pathway. Plos Pathogen 2008, 4(11):e1000197.
19. Marasco WA, Sui J*. The growth and potential of human anti-viral monoclonal antibody therapeutics. Nature Biotechnology (Invited Review) 2007, 25(12):1421-34.
20. Xu C, Sui J, Tao H, Zhu Q, Wayne A. Marasco. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-Region sulfation and define CXCR4 antigenic heterogeneity. J Immunol 2007,179(4):2408-18
21. Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA. Evaluation of human Mab 80r for immunoprophylaxis of SARS by an animal study, epitope mapping and analysis of spike variants. J Virol 2005, 79(10):5900-5906.
22. Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco WA, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in Vitro. Cancer Res 2005, 65(6):2344-2352
23. Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallrico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, and Marasco WA. Potent neutralization of SARS coronavirus Infection by a human monoclonal antibody against the ACE2-binding domain of spike protein. Proc Natl Acad Sci USA 2004,101(8):2536-41.
24. Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002, 303(1):9-14.
專利
Patents
1. Sui J, Liu H. Anti-FGF19 antibodies. Patent No. US222/0041706A1. 2022
2. Sui J, Li D, Li W. Anti-PreS1-HBV Antibodies. Patent No. US10544205B2. 2020
3. Marasco WA, Sui J. Human monoclonal anti-PD-L1 antibodies and methods of use. Patent No.: US10604581B2. 2020
4. Marasco WA, Sui J, Zhu Q, Kupper T. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use. Patent No. US9441045B2；JP6411329B2. 2018
5. Marasco WA, Sui J. Antibodies against H5N1 and methods of use thereof. Patent No. EP2222701B1；JP6149213B2；CA2708221C. 2017
6. Marasco WA, Sui J, Anvir Y. Humanized monoclonal antibodies and methods of use. Patent No. US9527924B2；EP2575882B1. 2016
7. Marasco WA, Sui J, Zhu Q, Kupper T. Humanized monoclonal antibodies and methods of use. Patent No. US9416169. 2016
8. Marasco WA, Sui J, Xu C. Antibodies against CXCR4 and methods of Use Thereof. Patent No. US8329178 B2; EP1871807 B1; CA2597717C. 2012
9. Marasco WA, Sui J. Antibodies against SARS-COV and methods of use thereof. Patent No. US7750123. 2010
